Form 4: ImmunityBio CEO Richard Adcock Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
CEO Richard Adcock of ImmunityBio, Inc. reports the vesting of restricted stock units (RSUs) and subsequent stock transactions.
Summary
- On February 22, 2025, Richard Adcock, CEO and President of ImmunityBio, Inc., reported transactions related to the vesting of restricted stock units (RSUs).
- A total of 152,439 shares were acquired upon the vesting of RSUs at a price of $0.
- Simultaneously, 78,167 shares were disposed of at a price of $3.42 to cover tax obligations.
- Following these transactions, Adcock directly owns 334,418 shares of ImmunityBio common stock and 304,878 restricted stock units.
- The RSUs vest in three annual installments, with the vesting commencement date being February 22, 2024.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders can monitor insider transactions to gain insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/22/2024 | Vesting commencement date for the RSU award |
| 02/21/2025 | Closing price of ImmunityBio, Inc.'s common stock used to calculate shares withheld |
| 02/22/2025 | Date of RSU vesting and stock transactions |
| 02/25/2025 | Date of signature for the SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.